MCID: LMY004
MIFTS: 63

Leiomyosarcoma

Categories: Cancer diseases, Muscle diseases, Rare diseases

Aliases & Classifications for Leiomyosarcoma

MalaCards integrated aliases for Leiomyosarcoma:

Name: Leiomyosarcoma 12 75 53 59 55 6 44 15 17 72
Leiomyosarcomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1967
MeSH 44 D007890
NCIt 50 C3158
SNOMED-CT 68 51549004
MESH via Orphanet 45 D007890
ICD10 via Orphanet 34 C49.9
UMLS via Orphanet 73 C0023269
Orphanet 59 ORPHA64720
UMLS 72 C0023269

Summaries for Leiomyosarcoma

NIH Rare Diseases : 53 Leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells. Leiomyosarcoma is a type of sarcoma. It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. The exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. It is most often found in the uterus or abdomen.

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to myxoid leiomyosarcoma and cutaneous leiomyosarcoma. An important gene associated with Leiomyosarcoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Oxaliplatin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and liver, and related phenotypes are cellular and behavior/neurological

Disease Ontology : 12 A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : 75 Leiomyosarcoma, is a malignant (cancerous) smooth muscle tumor. A benign tumor originating from the same... more...

Related Diseases for Leiomyosarcoma

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 815)
# Related Disease Score Top Affiliating Genes
1 myxoid leiomyosarcoma 34.6 PGR ACTC1
2 cutaneous leiomyosarcoma 34.4 FH DES ACTC1
3 epithelioid leiomyosarcoma 33.7 VIM SERPINA3 ENO2 DES ACTC1
4 small intestine leiomyosarcoma 33.6 KIT IGF2
5 gastric leiomyosarcoma 33.0 PDGFRA KIT IGF2 ENO2
6 smooth muscle tumor 31.3 VIM PGR KIT DES ACTC1
7 bizarre leiomyoma 31.2 PGR ACTC1
8 meningioma, radiation-induced 31.1 VIM S100B PGR
9 spindle cell sarcoma 31.0 VIM S100B MDM2 DES ACTC1
10 neurofibroma 30.9 S100B PDGFRA KIT
11 pleomorphic lipoma 30.9 PGR MDM2
12 spindle cell carcinoma 30.8 VIM PGR DES ACTC1
13 angiomyolipoma 30.8 PGR KIT DES ACTC1
14 fibrous histiocytoma 30.8 VIM SERPINA3 S100B DES ACTC1
15 benign breast phyllodes tumor 30.8 VIM PGR KIT
16 uterine carcinosarcoma 30.8 TP53 PGR KIT
17 sarcoma, synovial 30.8 VIM MDM2 KIT DES
18 hypereosinophilic syndrome 30.8 PDGFRB PDGFRA KIT
19 mesenchymoma 30.7 MDM2 MB DES
20 giant cell tumor 30.7 VIM SERPINA3 DES ACTC1
21 lipomatosis, multiple 30.7 MDM2 DES CDK4
22 carcinosarcoma 30.7 VIM TP53 PGR KIT DES ACTC1
23 myofibroma 30.6 PDGFRB MB DES
24 myxofibrosarcoma 30.6 S100B MDM2 DES
25 benign metastasizing leiomyoma 30.6 VIM PGR DES ACTC1
26 adenocarcinoma 30.6 TP53 PDGFRB KIT CDK4
27 teratoma 30.5 TP53 KIT ENO2 ACTC1
28 histiocytoma 30.5 TP53 SERPINA3 MDM2 MB KIT
29 malignant giant cell tumor 30.4 TP53 S100B ACTC1
30 amelanotic melanoma 30.4 VIM S100B KIT
31 gallbladder sarcoma 30.4 MYOG KIT DES
32 myoepithelioma 30.3 VIM S100B S100A1 ACTC1
33 fibromatosis 30.3 VIM KIT DES ACTC1
34 liposarcoma 30.3 VIM TP53 MDM2 MB DES CDK4
35 angiomyoma 30.3 MB KIT ENO2
36 orbit rhabdomyosarcoma 30.3 MYOG MB
37 diffuse peritoneal leiomyomatosis 30.2 WT1 PGR KIT
38 syringocystadenoma papilliferum 30.2 VIM S100B DES ACTC1
39 myxoid liposarcoma 30.2 TP53 MDM2 CDK4
40 spindle cell rhabdomyosarcoma 30.2 S100B MB DES
41 dedifferentiated liposarcoma 30.2 TP53 MDM2 DES CDK4 ACTC1
42 desmoid tumor 30.2 PDGFRB PDGFRA KIT
43 gastrointestinal system cancer 30.1 TP53 PDGFRA KIT
44 small cell carcinoma 30.1 TP53 PDGFRA KIT ENO2
45 sarcoma 30.1 WT1 VIM TP53 MDM2 KIT CDK4
46 epulis 30.1 VIM PGR ENO2 DES
47 leiomyoma 30.0 VIM S100A1 PGR KIT IGF2 FH
48 spinal meningioma 30.0 PGR IGF2 ENO2
49 neurilemmoma 30.0 VIM S100B PDGFRA KIT ENO2 DES
50 malignant fibroxanthoma 29.9 VIM SERPINA3 S100B MDM2 DES CDK4

Graphical network of the top 20 diseases related to Leiomyosarcoma:



Diseases related to Leiomyosarcoma

Symptoms & Phenotypes for Leiomyosarcoma

MGI Mouse Phenotypes related to Leiomyosarcoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 ACTC1 CDK4 DES ENO2 FH IGF2
2 behavior/neurological MP:0005386 10.44 CDK4 DES ENO2 IGF2 KIT MDM2
3 cardiovascular system MP:0005385 10.44 ACTC1 CDK4 DES IGF2 KIT MB
4 homeostasis/metabolism MP:0005376 10.44 ACTC1 CDK4 DES FH IGF2 KIT
5 growth/size/body region MP:0005378 10.35 ACTC1 CAPN6 CDK4 ENO2 IGF2 KIT
6 embryo MP:0005380 10.34 CDK4 IGF2 KIT MB MDM2 MYOG
7 muscle MP:0005369 10.34 ACTC1 CAPN6 CDK4 DES IGF2 KIT
8 mortality/aging MP:0010768 10.33 ACTC1 CDK4 DES FH IGF2 KIT
9 hematopoietic system MP:0005397 10.26 CDK4 IGF2 KIT MB MDM2 PDGFRA
10 endocrine/exocrine gland MP:0005379 10.2 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
11 integument MP:0010771 10.19 CDK4 IGF2 KIT MDM2 MYOG PDGFRA
12 craniofacial MP:0005382 10.18 CAPN6 ENO2 IGF2 KIT MDM2 PDGFRA
13 digestive/alimentary MP:0005381 10.17 CAPN6 CDK4 IGF2 KIT MDM2 PDGFRA
14 normal MP:0002873 10.1 ACTC1 CDK4 KIT MDM2 MYOG PDGFRA
15 limbs/digits/tail MP:0005371 10.02 IGF2 KIT MDM2 PDGFRA PDGFRB PGR
16 no phenotypic analysis MP:0003012 9.97 IGF2 KIT MDM2 MYOG PDGFRA PGR
17 neoplasm MP:0002006 9.95 CDK4 KIT MDM2 PDGFRA PGR TP53
18 renal/urinary system MP:0005367 9.81 CDK4 FH IGF2 KIT MDM2 PDGFRA
19 pigmentation MP:0001186 9.65 CDK4 KIT MDM2 PDGFRA TP53
20 reproductive system MP:0005389 9.65 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
21 respiratory system MP:0005388 9.32 ENO2 IGF2 KIT MB MYOG PDGFRA

Drugs & Therapeutics for Leiomyosarcoma

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 43805 6857599
2
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
3
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
4
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
8
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
9
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
12
Etoposide Approved Phase 3 33419-42-0 36462
13
Epirubicin Approved Phase 3 56420-45-2 41867
14 Olaratumab Approved, Investigational Phase 3 1024603-93-7
15
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
16
Gemcitabine Approved Phase 3 95058-81-4 60750
17
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
18
Lenograstim Approved, Investigational Phase 3 135968-09-1
19
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
20
Bevacizumab Approved, Investigational Phase 3 216974-75-3
21
Histamine Approved, Investigational Phase 3 51-45-6 774
22
Cyproheptadine Approved Phase 3 129-03-3 2913
23 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
24 Nucleic Acid Synthesis Inhibitors Phase 3
25 Hormone Antagonists Phase 3
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
27 Antiemetics Phase 3
28 Anti-Inflammatory Agents Phase 3
29 HIV Protease Inhibitors Phase 3
30 glucocorticoids Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Peripheral Nervous System Agents Phase 3
33
protease inhibitors Phase 3
34
Isophosphamide mustard Phase 2, Phase 3 0
35 Autonomic Agents Phase 3
36 Antirheumatic Agents Phase 3
37 Analgesics Phase 3
38 Liver Extracts Phase 3
39 Cola Phase 3
40 Central Nervous System Depressants Phase 3
41 Tranquilizing Agents Phase 3
42 Psychotropic Drugs Phase 3
43 Anti-Anxiety Agents Phase 3
44 Antipsychotic Agents Phase 3
45 Anesthetics, Intravenous Phase 3
46 Narcotics Phase 3
47 Analgesics, Opioid Phase 3
48 Adjuvants, Anesthesia Phase 3
49 Anesthetics, General Phase 3
50 Anesthetics Phase 3

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma Unknown status NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
3 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
4 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
5 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
6 Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
7 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
8 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
9 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
12 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
13 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
14 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
15 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
16 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
17 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
18 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
19 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
21 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
22 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
23 Randomised Phase III Multicentric Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin in Non-progressive Patients Versus Doxorubicine Alone as First-line Therapy in Patients With Metastatic or Unresectable Leiomyosarcoma (Uterine or Soft Tissue) Not yet recruiting NCT02997358 Phase 3 Doxorubicin;Trabectedin
24 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Not yet recruiting NCT04031677 Phase 3 Preoperative chemotherapy
25 A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
26 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
28 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
29 Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas Unknown status NCT01442662 Phase 2 pazopanib + gemcitabine
30 GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
31 A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
32 Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
33 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
34 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
35 A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
36 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
37 Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
38 A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas Completed NCT00379145 Phase 2 trabectedin
39 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
40 Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
41 A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma Completed NCT00310518 Phase 2 ARQ 501
42 A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma Completed NCT00093080 Phase 2 ridaforolimus
43 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
44 Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
45 A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
46 A Phase II Study of Mocetinostat Administered With Gemcitabine for Patients With Metastatic Leiomyosarcoma With Progression or Relapse Following Prior Treatment With Gemcitabine-Containing Therapy Completed NCT02303262 Phase 2 Mocetinostat;Gemcitabine
47 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01220609 Phase 2 Ixabepilone
48 A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
49 Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2 letrozole
50 A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Genetic Tests for Leiomyosarcoma

Anatomical Context for Leiomyosarcoma

MalaCards organs/tissues related to Leiomyosarcoma:

41
Uterus, Smooth Muscle, Liver, Lung, Bone, Breast, Small Intestine

Publications for Leiomyosarcoma

Articles related to Leiomyosarcoma:

(show top 50) (show all 9735)
# Title Authors PMID Year
1
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. 9 38
20081808 2010
2
Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value. 9 38
20437637 2010
3
Axillary and perianal leiomyosarcoma: report of two cases. 9 38
20495760 2010
4
WT-1 expression in gastrointestinal stromal tumours. 9 38
20025481 2010
5
A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. 9 38
19734847 2009
6
Gastric leiomyosarcoma manifesting peculiar findings: radiological-pathological correlation. 9 38
19432672 2009
7
Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. 9 38
18941404 2009
8
[Acute abdomen for perforated gastrointestinal stromal tumor (GIST). A case report]. 9 38
19537128 2009
9
Absence of fumarate hydratase mutation in a family with cutaneous leiomyosarcoma and renal cancer. 9 38
18986479 2008
10
Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. 9 38
18778186 2008
11
[Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. 9 38
18565690 2008
12
Clinicopathological characteristics of gastrointestinal mesenchymal tumors and diagnostic value of endoscopic ultrasonography. 9 38
18505417 2008
13
Breast metastasis from uterine leiomyosarcoma diagnosed by fine needle aspiration: a case report. 9 38
18702371 2008
14
Recurrent nodule on the nasal columella: a good reason to re-biopsy. 9 38
18613884 2008
15
Cytoplasmic overexpression of WT-1 in gastrointestinal stromal tumor and other soft tissue tumors. 9 38
18528287 2008
16
Immunohistochemical distinction of cutaneous spindle cell carcinoma. 9 38
18496422 2008
17
A rare tumor in the adrenal region: neuron-specific enolase (NSE)-producing leiomyosarcoma in an elderly hypertensive patient. 9 38
18250540 2008
18
[Adult prostate sarcoma: a report of 6 cases with clinical analysis]. 9 38
17725305 2007
19
Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells. 9 38
17368523 2007
20
Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis. 9 38
17550381 2007
21
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. 9 38
17396140 2007
22
Comparative study using rabbit-derived polyclonal, mouse-derived monoclonal, and rabbit-derived monoclonal antibodies for KIT immunostaining in GIST and other tumors. 9 38
17316415 2007
23
PDGFR-alpha as a potential therapeutic target in uterine sarcomas. 9 38
17049587 2007
24
C-kit protein expression in uterine and ovarian mesenchymal tumours. 9 38
17367465 2007
25
Esophageal mesenchymal tumors: endoscopy, pathology and immunohistochemistry. 9 38
17278201 2007
26
Nestin expression as a new marker in malignant peripheral nerve sheath tumors. 9 38
17300669 2007
27
Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors. 9 38
17129677 2007
28
Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis. 9 38
17291261 2007
29
[Gastrointestinal mesenchymal tumors: a clinical pathologic and immunohistochemical study of 210 cases]. 9 38
17253165 2007
30
A case of cutaneous leiomyosarcoma with overexpression of KIT: do CD117 (KIT)-positive primary gastrointestinal stromal tumours of the skin exist? 9 38
16634920 2006
31
Gastrointestinal stromal tumors: differential diagnosis. 9 38
17193824 2006
32
Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. 9 38
16625090 2006
33
No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. 9 38
15949892 2006
34
[Extragastrointestinal stromal tumors: a report of 4 cases]. 9 38
16472759 2006
35
Calretinin expression in tumors of adipose tissue. 9 38
16613326 2006
36
Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. 9 38
16330948 2006
37
The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. 9 38
15992918 2005
38
Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. 9 38
16160478 2005
39
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 9 38
16082245 2005
40
Primary osteosarcoma of the thoracic spine: report of an unusual elderly patient with autopsy findings. 9 38
15753962 2005
41
INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. 9 38
15761491 2005
42
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. 9 38
15894930 2005
43
Carcinosarcoma of the liver: a case report and review of the literature. 9 38
15913431 2005
44
Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects. 9 38
16033061 2005
45
So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity. 9 38
15864383 2005
46
[Malignant fibrous histiocytoma: pleomorphic sarcoma NOS or pleomorphic fibrosarcoma]. 9 38
15702318 2005
47
Intimal sarcoma of the pulmonary artery: report of an autopsy case. 9 38
16136754 2005
48
[Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. 9 38
15774214 2005
49
[Gastrointestinal stromal tumor: a clinicopathological study of 74 cases]. 9 38
15796874 2005
50
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. 9 38
15577680 2004

Variations for Leiomyosarcoma

ClinVar genetic disease variations for Leiomyosarcoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CHEK2 NM_007194.4(CHEK2): c.1100del (p.Thr367fs) deletion Conflicting interpretations of pathogenicity rs555607708 22:29091857-29091857 22:28695869-28695869

Cosmic variations for Leiomyosarcoma:

9 (show top 50) (show all 687)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6987318 ZFHX3 soft tissue,smooth muscle,leiomyosarcoma,NS c.2513A>G p.N838S 16:72957633-72957633 3
2 COSM212945 XPO1 soft tissue,smooth muscle,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 3
3 COSM6986268 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
4 COSM44683 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.652G>A p.V218M 17:7674879-7674879 3
5 COSM10704 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.844C>T p.R282W 17:7673776-7673776 3
6 COSM44732 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.512A>G p.E171G 17:7675100-7675100 3
7 COSM44327 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.518T>C p.V173A 17:7675094-7675094 3
8 COSM43615 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>C p.R158P 17:7675139-7675139 3
9 COSM307332 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.976G>A p.E326K 17:7673552-7673552 3
10 COSM44057 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.517G>C p.V173L 17:7675095-7675095 3
11 COSM1640842 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.641A>C p.H214P 17:7674890-7674890 3
12 COSM10790 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.455C>T p.P152L 17:7675157-7675157 3
13 COSM11224 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.394A>C p.K132Q 17:7675218-7675218 3
14 COSM43878 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.427G>A p.V143M 17:7675185-7675185 3
15 COSM10705 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.586C>T p.R196* 17:7674945-7674945 3
16 COSM43632 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 3
17 COSM10662 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.743G>A p.R248Q 17:7674220-7674220 3
18 COSM44238 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.631A>G p.T211A 17:7674900-7674900 3
19 COSM10735 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.638G>A p.R213Q 17:7674893-7674893 3
20 COSM10667 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.646G>A p.V216M 17:7674885-7674885 3
21 COSM43700 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.712T>A p.C238S 17:7674251-7674251 3
22 COSM43965 TP53 soft tissue,smooth muscle,leiomyoma,NS c.734G>C p.G245A 17:7674229-7674229 3
23 COSM44610 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.97-2A>T p.? 17:7676274-7676274 3
24 COSM43949 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.401T>G p.F134C 17:7675211-7675211 3
25 COSM43753 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.560-1G>A p.? 17:7674972-7674972 3
26 COSM45135 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.673-1G>T p.? 17:7674291-7674291 3
27 COSM13745 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.994-1G>C p.? 17:7670716-7670716 3
28 COSM10758 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.659A>G p.Y220C 17:7674872-7674872 3
29 COSM10656 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 17:7674221-7674221 3
30 COSM11476 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 3
31 COSM44537 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.595G>T p.G199* 17:7674936-7674936 3
32 COSM10690 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>A p.R158H 17:7675139-7675139 3
33 COSM11073 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 3
34 COSM10905 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.451C>T p.P151S 17:7675161-7675161 3
35 COSM10663 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.916C>T p.R306* 17:7673704-7673704 3
36 COSM10768 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.535C>T p.H179Y 17:7675077-7675077 3
37 COSM43989 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.596G>A p.G199E 17:7674935-7674935 3
38 COSM44415 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.711G>C p.M237I 17:7674252-7674252 3
39 COSM21585 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.376-2A>T p.? 17:7675238-7675238 3
40 COSM44190 TP53 soft tissue,liver,sarcoma,NS c.359A>T p.K120M 17:7676010-7676010 3
41 COSM10654 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.637C>T p.R213* 17:7674894-7674894 3
42 COSM10788 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.764T>G p.I255S 17:7674199-7674199 3
43 COSM10726 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.856G>A p.E286K 17:7673764-7673764 3
44 COSM43778 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.713G>T p.C238F 17:7674250-7674250 3
45 COSM44956 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.808T>G p.F270V 17:7673812-7673812 3
46 COSM11658 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.955A>T p.K319* 17:7673573-7673573 3
47 COSM44960 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.708C>G p.Y236* 17:7674255-7674255 3
48 COSM3849376 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.753C>G p.I251M 17:7674210-7674210 3
49 COSM10648 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.524G>A p.R175H 17:7675088-7675088 3
50 COSM44567 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.647T>C p.V216A 17:7674884-7674884 3

Copy number variations for Leiomyosarcoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 102985 16 58400001 69400000 Loss Leiomyosarcoma

Expression for Leiomyosarcoma

Search GEO for disease gene expression data for Leiomyosarcoma.

Pathways for Leiomyosarcoma

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 VIM TP53 PDGFRB PDGFRA MDM2 KIT
2
Show member pathways
12.94 TP53 PDGFRB PDGFRA MDM2 KIT IGF2
3
Show member pathways
12.75 TP53 PDGFRB PDGFRA MDM2 KIT IGF2
4
Show member pathways
12.73 TP53 PDGFRB PDGFRA MDM2 KIT CDK4
5 12.65 TP53 PDGFRB PDGFRA KIT IGF2
6
Show member pathways
12.64 TP53 PGR KIT IGF2 CDK4
7
Show member pathways
12.6 TP53 PDGFRB PDGFRA MDM2 CDK4
8
Show member pathways
12.6 TP53 PDGFRB PDGFRA MDM2 KIT
9 12.37 VIM TP53 PDGFRB PDGFRA MDM2
10 12.28 TP53 PDGFRB PDGFRA MDM2 KIT IGF2
11 12.26 TP53 PDGFRB PDGFRA CDK4
12
Show member pathways
12.22 TP53 PDGFRB PDGFRA MDM2 CAPN6
13
Show member pathways
12.13 TP53 PDGFRB PDGFRA KIT IGF2
14
Show member pathways
12.02 TP53 PDGFRB PDGFRA MDM2 CDK4
15 11.87 TP53 PDGFRB PDGFRA MDM2 CDK4
16 11.75 TP53 MDM2 CDK4
17 11.69 VIM S100B PDGFRA
18 11.65 TP53 MDM2 CDK4
19 11.63 VIM DES ACTC1
20 11.4 TP53 PDGFRB PDGFRA KIT
21 11.39 TP53 MDM2 CDK4
22 11.36 TP53 MDM2 CDK4
23 11.18 PDGFRA KIT IGF2 ACTC1
24 11.15 TP53 PDGFRB PDGFRA MDM2 IGF2 CDK4
25 11.14 TP53 MDM2 CDK4
26 10.87 VIM PDGFRB PDGFRA KIT IGF2 DES

GO Terms for Leiomyosarcoma

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 WT1 VIM TP53 S100B S100A1 PGR

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.83 PDGFRB PDGFRA KIT IGF2
2 positive regulation of gene expression GO:0010628 9.8 WT1 VIM TP53 MDM2 KIT ACTC1
3 positive regulation of MAPK cascade GO:0043410 9.78 PDGFRB PDGFRA KIT IGF2
4 cell chemotaxis GO:0060326 9.75 PDGFRB PDGFRA KIT
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.74 PDGFRB PDGFRA KIT
6 positive regulation of fibroblast proliferation GO:0048146 9.71 PDGFRB PDGFRA CDK4
7 muscle filament sliding GO:0030049 9.67 VIM DES ACTC1
8 retina vasculature development in camera-type eye GO:0061298 9.56 PDGFRB PDGFRA
9 metanephric mesenchyme development GO:0072075 9.55 WT1 PDGFRB
10 negative regulation of apoptotic process GO:0043066 9.55 WT1 TP53 PDGFRB MDM2 ACTC1
11 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.54 PDGFRB PDGFRA KIT
12 metanephric S-shaped body morphogenesis GO:0072284 9.51 WT1 PDGFRB
13 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.46 PDGFRB PDGFRA
14 metanephric glomerular capillary formation GO:0072277 9.43 PDGFRB PDGFRA
15 cardiac myofibril assembly GO:0055003 9.43 PDGFRB PDGFRA ACTC1
16 cellular response to actinomycin D GO:0072717 9.4 TP53 MDM2
17 positive regulation of cell proliferation GO:0008284 9.17 S100B PDGFRB PDGFRA MDM2 KIT IGF2
18 positive regulation of phospholipase C activity GO:0010863 9.13 PDGFRB PDGFRA KIT

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 VIM TP53 S100B S100A1 PGR MDM2
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 PDGFRB PDGFRA KIT
3 platelet-derived growth factor binding GO:0048407 9.32 PDGFRB PDGFRA
4 vascular endothelial growth factor binding GO:0038085 8.62 PDGFRB PDGFRA
5 protein binding GO:0005515 10.19 WT1 VIM TP53 SERPINA3 S100B S100A1

Sources for Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....